Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
Search
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
“Rare diseases are quite common”
Rare diseases are individually rare but collectively affect millions of people worldwide. Yet, they remain under-researched and are often misdiagnosed.
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
world rabies day 2019
world rabies day 2019
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Rahul Prasad
Rahul J. Prasad is a Senior Consultant with our Corporate Strategy & Consulting division – a job that suits his passion for data and his love of variety.
Cauliflower Risotto Video
This creamy risotto is full of great flavours and is easy to make in batches for family and friends.
Difficulties Chewing and Swallowing
Discover tips on how to overcome difficulties in chewing and swallowing food from Taking Cancer On Through Flavour
Clinical Studies
Clinical Studies
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Boehringer and ZEISS partnership eye diseases
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.
Rare Diseases: Rare but not alone
We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Vaccine bluetongue virus serotype 3 sheep cattle
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
Awards & International Recognition| Bioxcellence | Boehringer Ingelheim
Explore Bioxcellence's global recognition, showcasing our prestigious awards & certifications. Witness our commitment to excellence in biopharmaceuticals!
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.